CO2021015264A2 - Inhibidores de dihidroorotato deshidrogenasa - Google Patents

Inhibidores de dihidroorotato deshidrogenasa

Info

Publication number
CO2021015264A2
CO2021015264A2 CONC2021/0015264A CO2021015264A CO2021015264A2 CO 2021015264 A2 CO2021015264 A2 CO 2021015264A2 CO 2021015264 A CO2021015264 A CO 2021015264A CO 2021015264 A2 CO2021015264 A2 CO 2021015264A2
Authority
CO
Colombia
Prior art keywords
dehydrogenase inhibitors
dihydroorotate dehydrogenase
compounds
dihydroorotate
dhodh
Prior art date
Application number
CONC2021/0015264A
Other languages
English (en)
Inventor
Zhuming Zhang
Aihua Wang
Scott Kuduk
Lindsey Deratt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2021015264A2 publication Critical patent/CO2021015264A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, trastornos o afecciones médicas que son afectados por la modulación de DHODH. Tales compuestos se representan mediante la Fórmula (I) de la manera siguiente: en donde R1, R2, R3, R4, X y Y se definen en la presente descripción.
CONC2021/0015264A 2019-04-17 2021-11-11 Inhibidores de dihidroorotato deshidrogenasa CO2021015264A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835113P 2019-04-17 2019-04-17
PCT/IB2020/053601 WO2020212897A1 (en) 2019-04-17 2020-04-16 Dihydroorotate dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
CO2021015264A2 true CO2021015264A2 (es) 2021-11-19

Family

ID=70465152

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015264A CO2021015264A2 (es) 2019-04-17 2021-11-11 Inhibidores de dihidroorotato deshidrogenasa

Country Status (22)

Country Link
US (2) US11505536B2 (es)
EP (1) EP3956320B1 (es)
JP (1) JP2022530203A (es)
KR (1) KR20220002964A (es)
CN (1) CN114174278A (es)
AR (1) AR118724A1 (es)
AU (1) AU2020259384A1 (es)
BR (1) BR112021020520A2 (es)
CA (1) CA3136791A1 (es)
CL (1) CL2021002681A1 (es)
CO (1) CO2021015264A2 (es)
CR (1) CR20210520A (es)
EC (1) ECSP21081726A (es)
ES (1) ES2968809T3 (es)
IL (1) IL287268A (es)
MA (1) MA55716A (es)
MX (1) MX2021012706A (es)
PE (1) PE20220761A1 (es)
SG (1) SG11202111179RA (es)
TW (1) TW202104207A (es)
UY (1) UY38670A (es)
WO (1) WO2020212897A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116804004A (zh) * 2020-07-14 2023-09-26 南京征祥医药有限公司 作为dhodh抑制剂的化合物
WO2022070068A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) * 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
EP4313150A1 (en) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
EP4337216A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
WO2022237719A1 (en) 2021-05-11 2022-11-17 Janssen Pharmaceutica Nv Combination therapies
AU2022365100A1 (en) * 2021-10-13 2024-05-02 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085214A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
AU2014337064B2 (en) * 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
BR112017005238B1 (pt) * 2014-09-19 2023-01-17 Forma Therapeutics, Inc Derivados de piridin-2(1h)-ona quinolinona, seu uso e composição farmacêutica
EP3233857B1 (en) 2014-12-18 2020-03-11 Takeda Pharmaceutical Company Limited Solid state forms of fused heteroaromatic pyrrolidinones
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
CA3053068A1 (en) 2017-02-24 2018-08-30 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
EP3773523A4 (en) 2018-03-26 2021-12-29 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
TW202043208A (zh) 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2020161663A1 (en) 2019-02-07 2020-08-13 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors

Also Published As

Publication number Publication date
EP3956320A1 (en) 2022-02-23
CR20210520A (es) 2021-12-20
US11505536B2 (en) 2022-11-22
JP2022530203A (ja) 2022-06-28
SG11202111179RA (en) 2021-11-29
BR112021020520A2 (pt) 2021-12-07
TW202104207A (zh) 2021-02-01
WO2020212897A1 (en) 2020-10-22
UY38670A (es) 2020-10-30
AU2020259384A1 (en) 2021-11-11
MA55716A (fr) 2022-02-23
US11753393B2 (en) 2023-09-12
KR20220002964A (ko) 2022-01-07
AR118724A1 (es) 2021-10-27
CL2021002681A1 (es) 2022-05-27
PE20220761A1 (es) 2022-05-16
CA3136791A1 (en) 2020-10-22
EP3956320B1 (en) 2023-11-29
ECSP21081726A (es) 2021-12-30
MX2021012706A (es) 2022-01-31
CN114174278A (zh) 2022-03-11
IL287268A (en) 2021-12-01
ES2968809T3 (es) 2024-05-14
US20220298137A1 (en) 2022-09-22
US20200331881A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2021008400A (es) Inhibidores de dihidroorotato deshidrogenasa.
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX348024B (es) Compuestos de adamantilo.
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
MX2016006744A (es) Inhibidores de tirosina cinasa de bruton.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022002470A (es) Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
MX2022009535A (es) Compuestos heterociclicos como inhibidores de la dihidrorotata deshidrogenasa.
MX2016006351A (es) Inhibidores de tirosina cinasa de bruton.
BR112022012473A2 (pt) Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2022004335A (es) Biarilos como inhibidores de la dihidroorotato deshidrogenasa.